Analyst Price Targets — AVTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 2, 2026 11:10 am | — | Guggenheim | $50.00 | $15.11 | TheFly | Avalo Therapeutics initiated with a Buy at Guggenheim |
| December 17, 2025 9:14 pm | Joseph Catanzaro | Mizuho Securities | $39.00 | $19.25 | TheFly | Avalo Therapeutics initiated with an Outperform at Mizuho |
| September 17, 2025 3:35 pm | — | H.C. Wainwright | $25.00 | $11.33 | TheFly | Avalo Therapeutics price target raised to $25 from $15 at H.C. Wainwright |
| March 25, 2025 8:49 am | Kambiz Yazdi | Jefferies | $23.00 | $8.54 | TheFly | Avalo Therapeutics initiated with a Buy at Jefferies |
| April 16, 2024 6:50 am | Leland Gershell | Oppenheimer | $35.00 | $15.24 | StreetInsider | Oppenheimer Upgrades Avalo Therapeutics (AVTX) to Outperform following AVTX-009 acquisition |
Latest News for AVTX
Ally Bridge Group NY LLC acquired a new position in Avalo Therapeutics, Inc. (NASDAQ: AVTX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 178,100 shares of the company's stock, valued at approximately $2,264,000. Avalo Therapeutics comprises 1.4% of Ally Bridge Group
Avalo Therapeutics (NASDAQ: AVTX) CEO Garry Neil said the company expects to report top-line data in the second quarter from its completed Phase 2b LOTUS trial of AVTX-009 in hidradenitis suppurativa (HS), outlining what he described as operational execution milestones in 2025 and the rationale for targeting interleukin-1 beta (IL-1β) in the disease. Company focus and
Avalo Therapeutics (NASDAQ: AVTX - Get Free Report) and Silence Therapeutics (NASDAQ: SLN - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership. Insider and Institutional Ownership 87.1% of Avalo
WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: TD Cowen Annual Healthcare Conference Fireside Chat March 3, 2026, at 9:50 am ET Leerink Partners Global…
WAYNE, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to two new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AVTX.
U.S. House Trading
No House trades found for AVTX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.